Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.

Genomic subtypes including BCR::ABL1, BCR::ABL1-like, and KMT2A-R influence response and survival in adult B-ALL treated with blinatumomab plus chemotherapy.

• Why it matters: Understanding the genomic drivers of treatment response is crucial to optimize therapies and improve outcomes for adult B-ALL patients, as biological determinants of resistance remain unclear.
• What they did: The study analyzed genomic and clinical data from 569 adults with B-ALL, identifying 23 molecular subtypes and 267 driver genes, and examined how these relate to treatment response and survival.
• The result: Findings suggest that certain subtypes, such as hyperdiploid and PAX5alt, benefit more from blinatumomab addition, while mutations in TP53 and CHIP are linked to poorer outcomes, guiding personalized treatment strategies.